Skip to main content

Table 4 Comparison of genotype frequencies between RA patients with or without anti-TNF therapy, as marker of disease severity

From: Polymorphisms in genes controlling inflammation and tissue repair in rheumatoid arthritis: a case control study

SNP

Genotype frequency

p trenda

SNP

Genotype frequency

p trenda

 

No anti-TNF

Anti-TNF

  

No anti-TNF

Anti-TNF

 
 

250 n (%)

120 n (%)

  

250 n (%)

120 n (%)

 

IL6-174

   

NOS2a 608

   

C/C

33 (15.1)

22 (19.8)

0.06

G/G

175 (70.9)

75 (64.1)

0.18

C/G

83 (37.9)

49 (44.1)

 

G/A

65 (26.3)

37 (31.6)

 

G/G

103 (47.0)

40 (36.0)

 

A/A

7 (2.8)

5 (4.3)

 

IL8 781

   

PARP 762

   

C/C

97 (38.8)

43 (35.8)

0.92

T/T

180 (73.2)

75 (64.1)

0.37

C/T

108 (43.2)

58 (48.3)

 

T/C

55 (22.4)

41 (35.0)

 

T/T

45 (18.0)

19 (15.8)

 

C/C

11 (4.5)

1 (0.9)

 

PAI1 4/5G

   

IL4-524

   

5G/5G

67 (27.6)

33 (28.4)

0.97

C/C

177 (71.7)

87 (73.1)

0.62

5G/4G

116 (47.7)

53 (45.7)

 

C/T

60 (24.3)

29 (24.4)

 

4G/4G

60 (24.7)

30 (25.9)

 

T/T

10 (4)

3 (2.5)

 

TNFA-863

   

C1INH 480

   

C/C

155 (62.8)

78 (67.2)

0.42

G/G

143 (58.8)

65 (57.5)

0.62

C/A

87 (35.2)

36 (31.0)

 

G/A

82 (33.7)

45 (39.8)

 

A/A

5 (2.0)

2 (1.7)

 

A/A

18 (7.4)

3 (2.7)

 

TNFA-857

   

II10-1082

   

C/C

212 (87.2)

96 (84.2)

0.52

G/G

61 (25.7)

25 (21.9)

0.55

C/T

30 (12.3)

18 (15.8)

 

G/A

112 (47.3)

57 (50.0)

 

T/T

1 (0.4)

  

A/A

64 (27.0)

32 (28.1)

 

TNFA-376

   

IL10-819

   

G/G

248 (99.2)

118 (98.3)

0.45

C/C

153 (63.2)

75 (63.6)

0.72

G/A

2 (0.8)

2 (1.7)

 

C/T

65 (26.9)

34 (28.8)

 

A/A

   

T/T

24 (9.9)

9 (7.6)

 

TNFA-308

   

TLR4 299

   

G/G

156 (62.4)

89 (74.2)

0.13

A/A

206 (83.7)

104 (88.1)

0.24

G/A

91 (36.4)

26 (21.7)

 

A/G

39 (15.9)

14 (11.9)

 

A/A

3 (1.2)

5 (4.2)

 

G/G

1 (0.4)

  

TNFA-238

   

TLR4 399

   

G/G

243 (97.2)

111 (92.5)

0.04

C/C

206 (83.7)

103 (87.3)

0.34

G/A

7 (2.8)

9 (7.5)

 

C/T

39 (15.9)

15 (12.7)

 

A/A

   

T/T

1 (0.4)

  

IL1B-31

       

C/C

30 (12.0)

17 (14.3)

0.68

    

C/T

116 (46.4)

46 (38.6)

     

T/T

104 (41.6)

56 (47.1)

     
  1. Only patients for whom data regarding medication were complete (n = 370) were included.
  2. a. Cochrane-Armitage trend test for additive effects. p value represents analysis not corrected for multiple testing. When Bonferroni correction is applied none of the polymorphism tested remain significant.
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us